Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
Alain P. Algazi(University of California, San Francisco), Ryan J. Sullivan(Dana-Farber Cancer Institute), Adil Daud(Memorial Sloan Kettering Cancer Center), Josep M. Piulats(Institut Català d'Oncologia), Douglas B. Johnson(Vanderbilt University), Zeynep Eroglu(City Of Hope National Medical Center), Rodrigo Ramella Munhoz(Memorial Sloan Kettering Cancer Center), Bartosz Chmielowski(UCLA Health), Alexander N. Shoushtari(Memorial Sloan Kettering Cancer Center), Patrick A. Ott(Dana-Farber Cancer Institute), Jeffrey S. Weber(NYU Langone Health), Jeffrey A. Sosman(Palmetto Hematology Oncology), Richard D. Carvajal(Memorial Sloan Kettering Cancer Center), Katy K. Tsai(University of California, San Francisco), Jimmy J. Hwang(University of California, San Francisco), Michael A. Postow(Memorial Sloan Kettering Cancer Center)
Cited by 375
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k